Sorafenib for Advanced and Refractory Desmoid Tumors

Overview of attention for article published in New England Journal of Medicine, December 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

news: 17 news outlets
twitter: 112 X users
facebook: 2 Facebook pages
wikipedia: 1 Wikipedia page

googleplus: 1 Google+ user
reddit: 1 Redditor
guideline: 7 clinical guideline sources
bluesky: 1 Bluesky user

Readers on

mendeley: 279 Mendeley

So far, Altmetric has seen 1 Bluesky post from an account with 326 followers.

My friend Mrinal Gounder first author paper @NEJM congrats !!!! Sorafenib for Advanced and Refractory Desmoid Tumors | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa1805052#.XBrdd7OOa7E.twitter

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity.

Login to access the Sentiment Analysis related to this output.